treatment of non–small-cell lung cancer with erlotinib or gefitinib
TRANSCRIPT
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
N Engl J Med. 2011 Mar 10;364(10):947-55.
Presentor: CR Supervisor: Vs
1
Outline
• Introduction of lung cancer• EGFR in NSCLC• Important clinical trials of TKI• To know about gefitinib and erlotnib• Conclusion with NCCN guideline and
regulations of Bureau National health insurance, Taiwan, ROC
2
Lung cancer
• Leading cause of cancer-related death worldwide
• Estimated 157,300 deaths in the United States in 2010
• 85% of lung cancer are non-small-cell-lung cancer(NSCLC)
• Less than 30% respond to platinum based therapy
3
Chemotherapy in NSCLC
N Engl J Med 2002;346:92-984
General characteristicsN Engl J Med 2002;346:92-98
5
N Engl J Med 2002;346:92-98
TTP:GC >PC, greater grade 3,4,5 renal toxicity(9% vs. 3%) 6
N Engl J Med 2002;346:92-98
Overall survival7.8-8.1 months
Time to progression3.1-4.2 months
7
EGFR in NSCLC
8
Driver mutations in
NSCLC
Lancet Oncol 2011; 12: 175–809
EGFR signaling pathwaysHER3 had no tyrosinekinaseactivity
10
EGFR amplificationsEGFR amplifications11.Dysplasia.Dysplasia (especially of a (especially of a high grade)high grade)2. Increased lung2. Increased lung--cancer cancer risk when detected in the risk when detected in the sputum of smokersputum of smoker3. Poor prognosis 3. Poor prognosis 4.Sensitivity to EGFR 4.Sensitivity to EGFR inhibitorsinhibitors
N Engl J Med 2008; 359:1367-1380
11
EGFR mutation
12
EGFR mutation
N Engl J Med 2005;353:133-44.
Leu Arg Glu Ala (LREA) motif in exon 19Leu Arg Glu Ala (LREA) motif in exon 19
13
Gefitinib (Iressa) & Erlotinib(Tarceva)
• EGFR tyrosine kinase inhibitors• Asian, non-smoker, and female• Gefitinib and erlotinib for EGFR mutation
N Engl J Med 2008;359:1367-138014
Erlotinib in NSCLC( 2 lines)
N Engl J Med 2005; 353:123-132
Tarceva
Tarceva Placebo
15
N Engl J Med 2005; 353:123-13216
N Engl J Med 2002;346:92-98
Overall survivalHR:0.706.7 vs. 4.7 monthsP<0.001
Progression free survival2.2 vs 1.8 monthsP<0.001
17
Univariate HR P value Multivariate HR P valueTreatment
Erlotinib 0.7 <0.001 0.7 0.002Placebo
Pathologic subtypesAdenocarcinoma 0.7 0.008 0.8 0.004
Others 0.8 0.07EGFR
Positive 0.7 0.02Negative 0.9 0.7Unknown 0.8 0.03
SmokingEver 0.9 0.14 Referrence
Never 0.4 <0.001 0.8 0.048Unknown 1.1 0.8 1 0.89
RaceAsian 0.6 0.06 0.7 0.01
Others 0.8 0.01N Engl J Med 2002;346:92-98
18
N Engl J Med 2005;353:133-44.
Red (EGFR) Green (CEP7)
High polysomy ( 4 gene copies in 40% of cells)Amplification (gene:chromosome 2 or 15 gene copies per cell in 10% of cells)
High polysomy ( 4 gene copies in 40% of cells)Amplification (gene:chromosome 2 or 15 gene copies per cell in 10% of cells)
19
N Engl J Med 2005;353:133-44.20
N Engl J Med 2005;353:133-44.21
EGFR mutation
• 10% of adenocarcinoma in USA• 30-50% of adenocarcinoma in Asia• Female & non-smokers• Exons 18, 19, and 20 and 21• Transform fibroblasts and lung epithelial cells• In transgenic mice->exon 19 deletion or L858R
mutation->atypical adenomatous hyperplasia->BAC->invasive adenocarcinoma in 8-10 weeks
• >80% : exon 19 or the L858R within exon 21
N Engl J Med 2008; 359:1367-138022
Copy number alternations
(CNA) in Chromosome 7p
J Clin Oncol 2011 Sep 1;29(25):3435-42. 23
High-density comparative genomic hybridization (CGH) array
J Clin Oncol 2011 Sep 1;29(25):3435-42. 24
J Clin Oncol 2011 Sep 1;29(25):3435-42. 25
Iressa Survival Evaluation in Lung Cancer(ISEL)
Iressa Placebo Iressa Placebo
Lancet 2005;366:1527-1537
26
Overall survival in all populations5.6 vs. 5.1 months
Overall survial inadenocarcinoma6.3 vs. 5.4 months
Overall survial inadenocarcinoma6.3 vs. 5.4 months
HR:0.89,P=0.087
HR:0.84,P=0.089HR:0.84,P=0.089
Lancet 2005;366:1527-153727
Time to treatment failure in all populations3.0 vs. 2.6 months
HR:0.82,P=0.006
Lancet 2005;366:1527-153728
Subgroupanalysis of
Iressa
Subgroupanalysis of
Iressa
Lancet 2005;366:1527-153729
Iressa Pan-Asia Study
(IPASS)
Iressa Pan-Asia Study
(IPASS)
N Engl J Med 2009;361:947-957
1.Asia2.Iressa vs Carboplatin+Paclitaxel3.First line
1.Asia2.Iressa vs Carboplatin+Paclitaxel3.First line
30
Progression free survival in all populations5.6 vs. 5.1 months
Progression free survival in EGFR mutation6.3 vs. 5.4 months
Progression free survival in EGFR mutation6.3 vs. 5.4 months
HR:0.74,P<0.001
HR:0.48,P<0.001HR:0.48,P<0.001
N Engl J Med 2009;361:947-95731
Progression free survival in EGFR mutation negative5.6 vs. 5.1 months
Progression free survival in EGFR unknown6.3 vs. 5.4 months
Progression free survival in EGFR unknown6.3 vs. 5.4 months
HR:2.85,P<0.001
HR:0.68,P<0.001HR:0.68,P<0.001
N Engl J Med 2009;361:947-95732
Iressa vs.Paclitaxel+carboplatin
(1st line) in EGFR mutation
Iressa vs.Paclitaxel+carboplatin
(1st line) in EGFR mutation
N Engl J Med 2010; 362:2380-238833
Progression free survival10.8 vs. 5.4 months
Overall survival30.5 vs. 23.6 monthsOverall survival30.5 vs. 23.6 months
HR:0.30,P<0.001
P=0.31P=0.31
N Engl J Med 2010; 362:2380-238834
Erlotinib(Tarceva)
• Approval from FDA in November,2004• Approval from European Medicines Agency in
June,2005• Locally advanced or metastatic NSCLC• 2nd or 3rd line • 150mg/day PO QD• Bioavailability 100% when taken with food->
more side effect– One hour before or two hours after a meal
( Bioavailability:60%)35
Gefitinib (Iressa)• Approval from FDA in 2003• ISEL-> use in who are currently benefiting or have
previously benefited in USA• Approval from European Medicines Agency in July,2009
• Any line for NSCLC with EGFR mutations• In first line, inferior to chemotherapy but superior for
those with EGFR mutations• 2 line, similar to standard chemotherapy• Not effected by food• 250 mg PO QD• Half life: 48 hours• Bioavailability:60%
36
Metabolism
• By CYP3A4– CYP3A5 and CYP1A1( lesser)
• Careful with atazanavir, itraconazole,ritonavir,voriconazole, grape fruit juice
• Not with CYP3A4 inducers– rifampicin, phenytoin, and St. John’s wort
• Cigarrete induces CYP1A1 -> reduces erlotinib• Avoid H2 blocker or PPI (-> reduces gastric PH->
reduce plasma TKI)37
Follow-up
• Radiographic assessment no more frequent than every 6 to 8 weeks
• Visit at least monthly• Medications continued as long as
– ECOG adequate– No clinical or radiographic progression
38
Dosage
• Reduced when rash or diarrhea• Monitor liver function• Discontinued when total bilirubin 3X or
ALT/AST 5X• Erlotinib restated at a reduced dose with
decrement of 50mg ( 100mg qd)• Gefitinib restated at initial dose(250mg)
39
Cost
• Erlotinib– $4,000/month– NTD 53490/month(1783/#)
• Gefitinib– $1,800/month– NTD 41280/month(1376/#)
40
Toxic effects
• Discontinuation of drugs due to toxic effects– Erlotinib:5%– Geftinib:2%
• Erlotinib– Diarrhea : 55%– Severe diarreha: 6%
• Gefitinib– Diarrhea: 27 to 35%
• Stopped for up to 14 days until the symptoms resolved• Loperamide
41
Rash• 75% of erlotinib• 33% of geftinib• 7-14 days after initiation of therapy• Association with improved OS and PFS
– Surrogate indicator of effective EGFR inhibition?– Surrogate indicator of immue based local inflammatory
reaction?• Follicular and papulopustular• Face, scalp, chest, and back• Antibiotics, glucocorticoids, and immunomodulators• Moisturizing of the skin• Avoid acne preparations(benzoyl peroxide)• Dose modifications 42
Interstitial lung disease
• Less than 1% in white patients • About 5% in Japanese patients• 1st month of therapy• Risk factors
– previous chemotherapy– previous radiation to the lungs– preexisting parenchymal lung disease– metastatic lung disease– Concomitant pulmonary infection
• TKI permanently discontinued43
Neutrophilic infiltration of the dermis, involving most prominently theinfundibular portion of the hair follicles
44
Areas of uncertainty: other EGFR mutations?
Clin Cancer Res 2006;12:7232-724145
Resistance of TKI
• Almost for all• Median time to progression: 12 months• Secondary EGFR mutation
– T790M in exon 20 in 50%-70%– amplification of the MET oncogene in 30 to 50%
• Second generation TKI?– EKB-569 – HKI-272– XL647
J Thorac Oncol 2008;3:S146-946
TKI T790M resistance(Exon20)
47
Amplification of MET oncogene
48
Circulating tumor cells(CTC) chips
Nature 450, 1235-1239 (20 December 2007)49
Detection of EGFR mutation in blood
N Engl J Med 2008;359:366-77.
Red (CTC) Blue(CXR tumor burden)
50
ATLAS trial
• Chemotherapy + avastin-> Avastin + erlotinibvs. Avastin
• Avastin + erlotinib vs. Avastin + placebo– PFS: 4.8 vs. 3.7 months– P=0.001
J Clin Oncol 2009;27.51
BETA Lung Trial
• Phase 3• Avastin + erlotinib vs erlotinib• 2nd line for advanced NSCLC• PFS
– 3.4 vs. 1.7 months– P<0.001
Multidisciplinary Symposium in Thoracic Oncology, Chicago, November 2008.
52
Conclusion
53
NCCN guideline(Version 3.2011)
The National Comprehensive Cancer Network home page. (http://www.NCCN.org.)
54
NCCN guideline(Version 3.2011)
The National Comprehensive Cancer Network home page. (http://www.NCCN.org.)
55
NCCN guideline(Version 3.2011)
The National Comprehensive Cancer Network home page. (http://www.NCCN.org.)
All including SCC
56
Erlotinib1.
(1) 7097/6/1
(2) platinum docetaxel paclitaxel
2.
97/6/1(1)
70 ( )X
measurableevaluable 97/6/1
(2)platinum cisplatin carboplatin taxanes
paclitaxel docetaxelX measurable
evaluable97/6/1
(3)X
X57
Geftinib1.
(1) EGFR-TK(100/6/1)
(2) 70(96/11/1
100/6/1)2.
(1)EGFR-TK (100/6/1)
(2)70 ( )
Xmeasurable
evaluable
58
Thanks for your attention!
59